Project description
Affordable exoskeleton gets people walking
Experts have long been developing robotic exoskeletons to restore human movements. For widespread use, exoskeletons need to become more affordable. Current devices run for about EUR 100 000. ABLE Human Motion aspires to launch the first affordable and lightweight exoskeleton that helps restore the ability to walk for those with lower-limb paralysis. ABLE strives to do so in a natural and intuitive way, using an electric actuator that flexes and extends the leg, mimicking natural human movement. An inertial sensor is also used to detect the user intention to make the step forward. This patented and disruptive system to assist walking helps in palliating health issues caused by a sedentary lifestyle, while boosting self-confidence and independence.
Objective
People with lower-limb paralysis could walk again if they had a robotic exoskeleton to restore the leg movements affected by the injury. However, current devices are expensive (cost about 100 k€), heavy and require trained professional supervision. Therefore, they are only found in large hospitals and rehabilitation centers, and are out of the reach of the patient.
ABLE Human Motion is a medical device spin-off from Universitat Politècnica de Catalunya (UPC) that is developing and will commercialize robotic exoskeletons to enhance their mobility and independence. ABLE’s vision is to build a world where everybody has the possibility to move independently, with that aim we plan the launch of ABLE: the first home use, affordable and lightweight exoskeleton that restores the ability to walk of people with lower-limb paralysis in a natural and intuitive way. It is based on an electric actuator that flexes and extends the leg mimicking human natural movement, and an inertial sensor that together with dedicated algorithms detects the user’s intention to make the step forward. This patented and disruptive system to assist walking helps palliating health issues caused by sedentary lifestyle while boosting self-confidence and independence.
So far our newly established company has been awarded as an innovative technology to improve healthcare by CaixaImpulse and EIT Health. We have been selected among the 5 most promising medtech start-ups by MassMEDIC (Boston, USA). The team has also won the acceleration programs organized by Richi Foundation and CIMIT, the most successful health accelerator in the world. This has allowed us to validate the product-market fit with more than 150 stakeholders, establishing a viable business model and a go-to-market plan.
The project is currently at Technology Readiness Level (TRL) between 6 and 7, and should reach TRL9 within an 18-month timeframe.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences clinical medicine physiotherapy
- social sciences economics and business business and management business models
- engineering and technology electrical engineering, electronic engineering, information engineering electronic engineering sensors
- medical and health sciences basic medicine neurology stroke
- natural sciences computer and information sciences artificial intelligence machine learning
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
08042 Barcelona
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.